Wasatch Advisors Inc Allovir, Inc. Transaction History

Wasatch Advisors Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.68 - $2.39 $1.72 Million - $6.06 Million	-2,535,248 Reduced 40.12%	3,784,623 $2.57 Million
Q3 2023 Nov 14, 2023	SELL	$2.15 - $3.64 $697,120 - $1.18 Million	-324,242 Reduced 4.88%	6,319,871 $13.6 Million
Q2 2023 Aug 07, 2023	BUY	$3.17 - $5.82 $17.1 Million - $31.3 Million	5,384,194 Added 427.34%	6,644,113 $22.6 Million
Q1 2023 May 12, 2023	BUY	$3.94 - $7.05 $4.96 Million - $8.88 Million	1,259,919 New	1,259,919 $4.96 Million

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Wasatch Advisors Inc with notifications on news.